Edwards Lifesciences Penalized $12 Million for Structuring Deal to Evade Antitrust Filing

On July 13, 2026, the U.S. Federal Trade Commission (FTC) announced a settlement with Edwards Lifesciences Corp. and JC Medical’s parent company, Genesis MedTech Group Limited, resolving allegations of violations of the Hart-Scott-Rodino Antitrust Improvements Act (HSR Act). Under the proposed consent order, Edwards agreed to pay a $10 million civil penalty, while Genesis MedTech will pay $2 million, totaling $12 million—the largest penalty ever imposed for an HSR filing violation in U.S. history. The settlement is subject to a 30-day public comment period before the FTC can finalize the order.

The record fine stems from two strategic acquisitions Edwards pursued in July 2024 within the transcatheter aortic valve replacement for aortic regurgitation (TAVR-AR) space. Edwards acquired JC Medical, a subsidiary of Genesis MedTech, for $115 million and separately announced a planned $945 million acquisition of JenaValve Technology. Notably, JC Medical’s J-Valve system and JenaValve’s Trilogy system were the only two interventional devices undergoing clinical investigation in the U.S. for treating aortic regurgitation at the time.
In structuring the JC Medical acquisition, Edwards and Genesis MedTech set the purchase price at $115 million—deliberately just below the then-applicable HSR notification threshold of $119.5 million. Concurrently, Edwards made a $25 million equity investment in Genesis MedTech.

The FTC alleged that these transactions were interconnected in negotiation context, timing, and commercial purpose and should be aggregated. Combining the $115 million acquisition with the $25 million investment exceeded the notification threshold. The FTC’s complaint further asserted that Edwards and Genesis MedTech intentionally structured the deal to circumvent HSR filing obligations. Internal communications cited in the complaint revealed that Edwards explicitly described the transaction structure as designed to “stay below the [filing] threshold.” By failing to submit a required HSR filing and observe the statutory waiting period before closing, Edwards committed a substantive violation.

One day after closing the JC Medical transaction, Edwards moved to acquire its sole rival, JenaValve. The FTC filed suit in August 2025, arguing that allowing the JenaValve acquisition would consolidate the only two U.S. firms advancing TAVR-AR clinical trials under a single entity, creating an irreversible monopoly. In January 2026, the U.S. District Court for the District of Columbia, following a six-day evidentiary hearing, granted the FTC’s motion for a preliminary injunction, compelling Edwards to abandon the JenaValve deal.

Beyond monetary penalties, the settlement imposes ongoing compliance obligations on Edwards. For five years, Edwards must provide advance written notice to the FTC before acquiring any U.S. entity that sells, conducts clinical trials for, or holds an FDA Investigational Device Exemption (IDE) for a TAVR-AR device. Edwards must also implement and maintain a systematic antitrust compliance program. Edwards has agreed to pay the penalty while denying any violation or wrongdoing. China Intellectual Property Lawyer Network will continue to monitor further developments.